Impact of Adipose Tissue in COVID-19

Study Overview
=================
Brief Summary
-----------------
Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.

Official Title
-----------------
Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Adipose tissue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than or equal to 18 years All patients who are obese or overweight (> 25 kg/m2) or non-obese (< or = 25 kg/m2) operated for abdominal vascular surgery Beneficiary or entitled to a social security scheme (except AME) Exclusion Criteria: Pregnant or breastfeeding woman Patient refusal Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese or overweight patients<br> | Other: Adipose tissue<br>* Adipose tissue sampling<br>|
| Patients without overweight<br> | Other: Adipose tissue<br>* Adipose tissue sampling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue. | Analysis of the expression of mRNA and ACE2 and TMPRSS2 proteins in the subcutaneous and visceral adipose tissue of normal weight and obese patients | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue | Infection of human adipocytes in lean and obese subjects by SARS-CoV-2 | 12 months | 
| Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue. | Assessment of the expression and secretion of inflammatory cytokines (TNF-α, IL-1 , IL-4 , IL-6 , IL-7 , IL-10 , IL-12 , IL-13 , IL-18 ¸ IL-23, INF-α, INF-β) after infection with SARS-CoV-2 of adipose tissue / adipocytes of thin and obese subjects. Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects. | 12 months | 
| Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue. | Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects. | 12 months | 
| Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis. | Study whether infection with SARS-CoV-2 activates the RE stress pathways in adipose tissue | 12 months | 
| Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue | Use of RE stress inhibitors on adipocytes infected with SARS-CoV-2 and assess their effect on the maturation of the virus in infected cells. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adipose tissue, Covid19, SARS-CoV2